News headlines about Chiasma (NASDAQ:CHMA) have been trending somewhat positive this week, according to Accern Sentiment. Accern identifies negative and positive media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Chiasma earned a coverage optimism score of 0.13 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 44.7582899450584 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Shares of Chiasma (NASDAQ:CHMA) opened at $1.48 on Friday. The firm has a market cap of $37.45, a PE ratio of -1.26 and a beta of 1.20. Chiasma has a 52 week low of $1.25 and a 52 week high of $2.95.
COPYRIGHT VIOLATION WARNING: This news story was first reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of international copyright & trademark laws. The correct version of this news story can be viewed at https://www.thelincolnianonline.com/2018/01/14/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-chiasma-chma-share-price-updated-updated.html.
Chiasma Company Profile
Chiasma, Inc is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body’s production of excess growth hormone.
Receive News & Ratings for Chiasma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chiasma and related companies with MarketBeat.com's FREE daily email newsletter.